BBSRC alliance helps boost Babraham board
The board of Babraham Bioscience Technologies (BBT), which develops and manages the Babraham Research Campus, has welcomed Dr Karen Lewis, as non-executive director.
Karen has been nominated by the Biotechnology and Biological Sciences Research Council (BBSRC) to represent its interests in driving and overseeing the future strategy and development of the campus.
BBSRC forms part of UK Research & Innovation, an executive non-departmental public body, which is one of two shareholders of BBT. The other shareholder is the Babraham Institute.
Karen is executive director, of Capability and Innovation at BBSRC. She has been involved in developing the BBSRC research and innovation campus strategy, establishing knowledge exchange and commercialisation teams and has worked on BBSRC’s bioeconomy strategy enabling bioscience research to deliver benefit and impact for the UK.
She joins the seven-strong BBT board, which includes Professor Clive Page, the Babraham Institute nominee director and independent non-executive directors Dr Jane Osbourn (MedImmune), Jo Parfrey, and chair Dr Andy Richards. BBT’s chief executive Derek Jones and CFO Becky Paxton are the executive directors on the board.
With a PhD in microbiology and experience in commercial research and development within biotechnology companies, in addition to her BBSRC roles, Karen is well placed to support the Babraham Research Campus’ mission to be the best place in Europe to start-up and scale-up a life science business.
“We are pleased to welcome Karen to the board,” said BBT CEO Derek Jones. “She brings a wealth of knowledge and experience that will further strengthen and diversify our board, and we look forward to benefiting from her skills and perspective.”